# Evaluation of SC Injected Tc 99m Tilmanocept Localization in Active RA Subjects by SPECT and SPECT/CT Imaging

> **NCT02683421** · PHASE1 · COMPLETED · sponsor: **Navidea Biopharmaceuticals** · enrollment: 18 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Tilmanocept

## Key facts

- **NCT ID:** NCT02683421
- **Lead sponsor:** Navidea Biopharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2019-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02683421

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02683421, "Evaluation of SC Injected Tc 99m Tilmanocept Localization in Active RA Subjects by SPECT and SPECT/CT Imaging". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT02683421. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*